BioCentury
ARTICLE | Top Story

FDA approves tofacitinib for RA

November 7, 2012 2:05 AM UTC

FDA approved an NDA from Pfizer Inc. (NYSE:PFE) for Xeljanz tofacitinib to treat moderate to severe rheumatoid arthritis in adults with an inadequate response or intolerance to methotrexate. Xeljanz may be used as monotherapy or in combination with methotrexate or non-biologic DMARDs. Pfizer plans to launch the oral pan-Janus kinase (JAK) inhibitor in the next three weeks with a wholesale acquisition cost of $2,055.13 for a 30-day supply. Tofacitinib is the first oral JAK inhibitor approved by FDA for RA. ...